Siga Technologies (NASDAQ:SIGA) Announces Quarterly Earnings Results

Siga Technologies (NASDAQ:SIGA) released its quarterly earnings data on Thursday. The company reported ($0.05) EPS for the quarter, FiscalAI reports. The company had revenue of $6.24 million during the quarter. Siga Technologies had a return on equity of 9.92% and a net margin of 21.58%.

Here are the key takeaways from Siga Technologies’ conference call:

• SIGA expects approximately $13 million of oral TPOXX deliveries to an international customer in Q2 plus additional IV TPOXX shipments to the U.S. SNS, which should materially boost near-term product revenue versus Q1.
• The company reported a strong balance sheet with about $146 million in cash and no debt at March 31, 2026, and paid a $0.60 special cash dividend while stating pro forma cash would remain above $100 million.
• The CHMP recommended withdrawing the mpox indication in Europe (while reaffirming smallpox, cowpox and vaccinia), which could limit EU label-based use and potential demand beyond core smallpox stockpiling.
• SIGA entered an exclusive licensing and distribution agreement with Hikma for the MENA region, with SIGA as the exclusive finished-product supplier, positioning the company to access underrepresented markets (financial terms confidential).
• Pipeline progress includes a filed IND and initiated Phase I pediatric study with results expected in H2 2026, and targeting an FDA submission for a post-exposure prophylaxis (PEP) indication within the next 12 months, representing regulatory catalysts.

Siga Technologies Price Performance

NASDAQ SIGA traded up $0.07 during mid-day trading on Friday, hitting $4.80. The stock had a trading volume of 1,079,699 shares, compared to its average volume of 459,972. The firm’s 50 day moving average is $5.13 and its 200 day moving average is $6.15. Siga Technologies has a twelve month low of $4.29 and a twelve month high of $9.62. The stock has a market capitalization of $344.26 million, a price-to-earnings ratio of 17.78 and a beta of 0.93.

Siga Technologies Dividend Announcement

The company also recently disclosed a special dividend, which was paid on Thursday, April 23rd. Investors of record on Tuesday, April 7th were paid a $0.60 dividend. The ex-dividend date of this dividend was Tuesday, April 7th.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Siga Technologies from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, April 10th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Siga Technologies has an average rating of “Sell”.

Institutional Trading of Siga Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of SIGA. Farther Finance Advisors LLC increased its stake in shares of Siga Technologies by 418.1% in the 4th quarter. Farther Finance Advisors LLC now owns 4,150 shares of the company’s stock worth $25,000 after acquiring an additional 3,349 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Siga Technologies by 34.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,661 shares of the company’s stock worth $30,000 after acquiring an additional 1,184 shares during the last quarter. CWM LLC increased its stake in shares of Siga Technologies by 148.6% in the 4th quarter. CWM LLC now owns 5,027 shares of the company’s stock worth $31,000 after acquiring an additional 3,005 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of Siga Technologies in the 3rd quarter worth $34,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Siga Technologies by 116.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,817 shares of the company’s stock worth $44,000 after acquiring an additional 3,669 shares during the last quarter. 55.40% of the stock is owned by institutional investors and hedge funds.

Siga Technologies Company Profile

Siga Technologies, Inc (NASDAQ: SIGA) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of medical countermeasures for public health emergencies and biological threats. The company’s flagship product, TPOXX® (tecovirimat), is the first and only antiviral approved by the U.S. Food and Drug Administration for the treatment of smallpox. Siga has entered into procurement and development contracts with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, to supply TPOXX® for the Strategic National Stockpile.

Founded in 2002, Siga has built a pipeline of therapies targeting high-consequence pathogens such as smallpox, plague and other potential biothreat agents.